Dominica vs Grenada: Statin use vs. average non-HDL cholesterol levels
Dominica
3.5
in 2018
Grenada
3.5
in 2018
Dominica rank
52nd
Grenada rank
52nd
Statin use vs. average non-HDL cholesterol levels over time
- Dominica
- Grenada
How they compare
Dominica currently reports 3.5 against 3.5 in Grenada, a difference of 0.
The two have swapped places 1 time across 39 shared years of data; in 1980 it was Dominica ahead.
Dominica ranks 52nd and Grenada ranks 52nd of 191 countries.
Dominica has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Dominica | Grenada | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 3.46 | 3.2 | 0.26 | Dominica |
| 1990s | 3.6 | 3.25 | 0.35 | Dominica |
| 2000s | 3.51 | 3.33 | 0.18 | Dominica |
| 2010s | 3.5 | 3.46 | 0.0444 | Dominica |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Dominica or Grenada?
- Dominica, at 3.5 against 3.5 in Grenada as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Dominica and Grenada?
- 0, with Dominica ahead.
- How many years of comparable data are there for Dominica and Grenada?
- 39 years are reported by both, from 1980 to 2018.
- How do Dominica and Grenada rank globally for statin use vs. average non-hdl cholesterol levels?
- Dominica ranks 52nd and Grenada ranks 52nd of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.